Trial reportDiabetologia2018
Clinical and metabolic features of the randomised controlled Diabetes Remission Clinical Trial (DiRECT) cohort.
Trial report in Diabetologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia.The Cochrane database of systematic reviews · 2018Pooled it
- Changes in quantity plant-based protein intake on type 2 diabetes remission in coronary heart disease patients: from the CORDIOPREV study.European journal of nutrition · 2023Trial
- Antihypertensive medication needs and blood pressure control with weight loss in the Diabetes Remission Clinical Trial (DiRECT).Diabetologia · 2021Trial
- Trial
- Proactive case-finding and risk-stratification in people at risk of chronic liver disease in Greater Manchester: a cost-effectiveness analysis.BMJ public health · 2026Article
- The Twin Cycle Hypothesis of type 2 diabetes aetiology: From concept to national NHS programme.Experimental physiology · 2025Review
- Aetiology of type 2 diabetes: an experimental medicine odyssey.Diabetologia · 2025Review
- Effect of Lifestyle Intervention on the Mobilization of Fat Depots and Organ Iron Deposition in Individuals with Obesity: A Prospective Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- What Not to Overlook in the Management of Patients with Type 2 Diabetes Mellitus: The Nephrological and Hepatological Perspectives.International journal of molecular sciences · 2024Review
- The metabolomic signature of weight loss and remission in the Diabetes Remission Clinical Trial (DiRECT).Diabetologia · 2024Article
- Lifestyle medicine: a cultural shift in medicine that can drive integration of care.Future healthcare journal · 2023Article
- Effects of Dietary App-Supported Tele-Counseling on Sodium Intake, Diet Quality, and Blood Pressure in Patients With Diabetes and Kidney Disease.Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation · 2022Article
- Implementation of a community-based low-calorie dietary intervention for the induction of type-2 diabetes and pre-diabetes remission: a feasibility study utilising a type 2 hybrid design.Implementation science communications · 2021Article
- Therapeutic potential of mitochondrial uncouplers for the treatment of metabolic associated fatty liver disease and NASH.Molecular metabolism · 2021Review
- Barocrinology: The Endocrinology of Obesity from Bench to Bedside.Medical sciences (Basel, Switzerland) · 2020Review
- Heterogeneity in the uptake, attendance, and outcomes in a clinical trial of a total diet replacement weight loss programme.BMC medicine · 2020Article
- Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities.International journal of molecular sciences · 2020Review
- Pathogenesis of Insulin Resistance and Atherogenic Dyslipidemia in Nonalcoholic Fatty Liver Disease.Journal of clinical and translational hepatology · 2019Review
- Article
- Within-trial cost and 1-year cost-effectiveness of the DiRECT/Counterweight-Plus weight-management programme to achieve remission of type 2 diabetes.The lancet. Diabetes & endocrinology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
aims/hypothesisSubstantial weight loss in type 2 diabetes can achieve a return to non-diabetic biochemical status, without the need for medication. The Diabetes Remission Clinical Trial (DiRECT), a cluster-randomised controlled trial, is testing a structured intervention designed to achieve and sustain this over 2 years in a primary care setting to determine practicability for routine clinical practice. This paper reports the characteristics of the baseline cohort.
methodsPeople with type 2 diabetes for <6 years with a BMI of 27-45 kg/m
resultsOf 1510 people invited, 423 (28%) accepted; of whom, 306 (72%) were eligible at screening and gave informed consent. Seven participants were later found to have been randomised in error and one withdrew consent, leaving 298 (176 men, 122 women) who will form the intention to treat (ITT) population for analysis. Mean (SD) age was 54.4 (7.6) years, duration of diabetes 3.0 (1.7) years, BMI 34.6 (4.4) kg/m CONCLUSIONS/
interpretationDiRECT has recruited a cohort of people with type 2 diabetes with characteristics similar to those seen in routine practice, indicating potential widespread applicability. Over 25% of the eligible population wished to participate in the study, including a high proportion of men, in line with the prevalence distribution of type 2 diabetes.
trial registrationwww.controlled-trials.com/ISRCTN03267836 ; date of registration 20 December 2013.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.